Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.2009017117 http://scihub22266oqcxt.onion/10.1073/pnas.2009017117 32699149!7430998!32699149     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Proc+Natl+Acad+Sci+U+S+A 2020 ; 117 (32): 18951-18953 Nephropedia Template TP {{tp|p=32699149|t=2020. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 |pdf=|usr=}}{{32699149}} gab.com Text Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=32699149 #FOAvip Around the tenth day after diagnosis, approximately 20% of patients with coronavirus disease 2019 (COVID-19)-associated pneumonia evolve toward severe oxygen dependence (stage 2b) and acute respiratory distress syndrome (stage 3) associated with systemic inflammation often termed a "cytokine storm." Because interleukin-1 (IL-1) blocks the production of IL-6 and other proinflammatory cytokines, we treated COVID-19 patients early in the disease with the IL-1 receptor antagonist, anakinra. We retrospectively compared 22 patients from three different centers in France with stages 2b and 3 COVID-19-associated pneumonia presenting with acute severe respiratory failure and systemic inflammation who received either standard-of-care treatment alone (10 patients) or combined with intravenous anakinra (12 patients). Treatment started at 300 mg?d(-1) for 5 d, then tapered with lower dosing over 3 d. Both populations were comparable for age, comorbidities, clinical stage, and elevated biomarkers of systemic inflammation. All of the patients treated with anakinra improved clinically (P < 0.01), with no deaths, significant decreases in oxygen requirements (P < 0.05), and more days without invasive mechanical ventilation (P < 0.06), compared with the control group. The effect of anakinra was rapid, as judged by significant decrease of fever and C-reactive protein at day 3. A mean total dose of 1,950 mg was infused with no adverse side effects or bacterial infection. We conclude that early blockade of the IL-1 receptor is therapeutic in acute hyperinflammatory respiratory failure in COVID-19 patients. Twit Text FOAVip Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=32699149 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32699149 #FOAvip English Wikipedia <ref>{{Cite pmid|32699149}}</ref> Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 #MMPMID32699149 Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G Proc Natl Acad Sci U S A 2020[Aug]; 117 (32): 18951-18953 PMID32699149show ga Around the tenth day after diagnosis, approximately 20% of patients with coronavirus disease 2019 (COVID-19)-associated pneumonia evolve toward severe oxygen dependence (stage 2b) and acute respiratory distress syndrome (stage 3) associated with systemic inflammation often termed a "cytokine storm." Because interleukin-1 (IL-1) blocks the production of IL-6 and other proinflammatory cytokines, we treated COVID-19 patients early in the disease with the IL-1 receptor antagonist, anakinra. We retrospectively compared 22 patients from three different centers in France with stages 2b and 3 COVID-19-associated pneumonia presenting with acute severe respiratory failure and systemic inflammation who received either standard-of-care treatment alone (10 patients) or combined with intravenous anakinra (12 patients). Treatment started at 300 mg?d(-1) for 5 d, then tapered with lower dosing over 3 d. Both populations were comparable for age, comorbidities, clinical stage, and elevated biomarkers of systemic inflammation. All of the patients treated with anakinra improved clinically (P < 0.01), with no deaths, significant decreases in oxygen requirements (P < 0.05), and more days without invasive mechanical ventilation (P < 0.06), compared with the control group. The effect of anakinra was rapid, as judged by significant decrease of fever and C-reactive protein at day 3. A mean total dose of 1,950 mg was infused with no adverse side effects or bacterial infection. We conclude that early blockade of the IL-1 receptor is therapeutic in acute hyperinflammatory respiratory failure in COVID-19 patients. |Aged[MESH] |Anti-Inflammatory Agents/administration & dosage/*therapeutic use[MESH] |COVID-19[MESH] |Case-Control Studies[MESH] |Coronavirus Infections/complications/*drug therapy[MESH] |Female[MESH] |Humans[MESH] |Immunologic Factors/administration & dosage/*therapeutic use[MESH] |Injections, Intravenous[MESH] |Interleukin 1 Receptor Antagonist Protein/administration & dosage/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*drug therapy/etiology[MESH]Early IL-1 receptor blockade in severe inflammatory respiratory failur(epmc).pdf DeepDyve Pubget Overpricing